Nuclear Medicine Oncology and Radiotherapy Institute (NORI) has acquired a cyclotron, valued at Rs 1.5 billion, to produce Gallium 68 isotopes for Positron Emission Tomography (PET) scans. This new technology will significantly improve cancer diagnosis and make these life-saving services more accessible to patients within a 200-kilometer radius of Islamabad. Previously, these isotopes were only available in Lahore, which created difficulties for patients in northern Pakistan due to the short half-life of the isotopes, preventing timely transportation.
Dr. Muhammad Faheem, Director of NORI, explained that the new cyclotron would address this issue by enabling local production of Gallium 68 isotopes, making timely diagnostics available to a larger number of patients. PET scans, which detect biochemical activity in tissues, play a critical role in early cancer detection and treatment planning.
NORI, which operates under a “no-refusal” policy, has been a leading center for cancer treatment in Pakistan. This policy, along with its network of 19 affiliated Atomic Energy Commission Cancer Hospitals (AECHs), has enabled NORI to treat 80% of the country’s cancer patients. The hospital also offers a 40% discount on in-patient medications, ensuring affordability for all patients.
Since its establishment in 1983, NORI has become a premier institution for cancer care. The hospital has contributed to developing a national cancer data registry and running awareness campaigns. Dr. Shazia Fatima, Director General of the Nuclear Medicine and Oncology Centre, emphasized that early diagnosis significantly reduces treatment costs and improves patient outcomes. NORI’s contributions also extend to producing essential medicines through the Pakistan Institute of Nuclear Science and Technology (PINSTECH), saving the country millions in foreign exchange annually.
In 2023, NORI received recognition from the International Atomic Energy Agency (IAEA) as a “Ray of Hope” for its dedication to improving cancer care in Pakistan. NORI’s impact is highlighted by success stories like that of Mohammad Zia, a cancer survivor who was misdiagnosed at private hospitals but received accurate treatment at NORI, ultimately becoming cancer-free.
The acquisition of the cyclotron and NORI’s continued focus on improving diagnostic and treatment technologies further solidifies its role as a leader in cancer care, offering patients hope and better chances of survival.
